This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
Majority of organizations are looking to increase investments in public and hybrid cloud
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Morepen Labs successfully raised Rs. 200 Crore through QIP
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
